Monotherapy for estrogen-receptor +ve, locally advanced or metastatic breast cancer in postmenopausal women not previously treated w/ endocrine therapy, or w/ disease relapse on or after adjuvant anti-estrogen therapy, or disease progression on anti-estrogen therapy. In combination w/ palbociclib for hormone receptor (HR)-+ve, human epidermal growth factor receptor 2 (HER2) -ve locally advanced or metastatic breast cancer in women who received prior endocrine therapy; combined w/ LH releasing hormone (LHRH) agonist in pre- or perimenopausal women.
Adult female including elderly 500 mg at 1-mth intervals w/ additional 500 mg given 2 wk after initial dose, administered 1 in each buttock as 2 consecutive 5 mL slow IM inj.
Bleeding diatheses, thrombocytopenia; critical visceral disease; thromboembolic events in women w/ advanced breast cancer; potential risk of osteoporosis. Dorsogluteal inj site due to proximity of underlying sciatic nerve. Interfered w/ Ab based-estradiol assays. Concomitant use w/ anticoagulants. May affect ability to drive & use machines. Mild to moderate hepatic impairment. Severe renal impairment (CrCl <30 mL/min). Women of childbearing potential should use effective contraception while on treatment. Pregnancy & lactation. Not recommended in childn or adolescents.
Sign Out
